Cytiva OligoProcess™ High-Throughput Oligonucleotide Synthesizer
| Brand | Cytiva |
|---|---|
| Origin | Sweden |
| Instrument Type | High-Throughput |
| Synthesis Scale Range | 10–1800 µmol |
| Explosion-Proof Design | Yes |
| Industrial-Grade Components | Yes |
| Regulatory Compliance | GMP-Ready, Supports FDA 21 CFR Part 11 & EU Annex 11 |
| Software Platform | UNICORN® v7.x or later |
| Scalability | Linear lab-to-commercial scale-up |
| Annual Production Capacity | Up to hundreds of kilograms (kg/yr), extendable to metric tons under continuous operation |
Overview
The Cytiva OligoProcess™ High-Throughput Oligonucleotide Synthesizer is an industrial-grade solid-phase DNA/RNA synthesizer engineered for reproducible, scalable, and regulatory-compliant manufacturing of therapeutic oligonucleotides. It operates on the phosphoramidite chemistry principle—employing automated, stepwise coupling, oxidation, capping, and deblocking cycles under inert atmosphere control—to deliver high-fidelity sequences across a broad synthesis scale range (10–1800 µmol per synthesis run). Designed specifically for clinical-stage development and commercial GMP production, the system integrates explosion-proof engineering, corrosion-resistant fluidic pathways, and redundant safety interlocks to safely handle aggressive reagents including acetonitrile, dichloroacetic acid, and oxidizing agents. Its architecture enables direct translation of process parameters from benchtop R&D to pilot and full-scale manufacturing without re-optimization—ensuring batch consistency, traceability, and compliance with ICH Q5A, Q5B, and Q7 guidelines.
Key Features
- Explosion-proof enclosure certified to ATEX/IECEx Zone 1 standards for safe operation in Class I, Division 1 hazardous environments.
- Modular fluidic architecture with chemically inert wetted materials (e.g., PFA, Hastelloy®, sapphire valves) ensuring long-term compatibility with aggressive synthesis reagents.
- High-precision mass-flow-controlled reagent delivery enabling consistent coupling efficiency (>99.5% per step, typical for optimized phosphoramidite protocols).
- Multi-channel synthesis capability supporting parallel synthesis of up to 24 columns (configurable) with independent pressure and timing control per channel.
- Integrated environmental monitoring (temperature, humidity, O2, solvent vapor) with real-time logging and alarm thresholds aligned with ISO 14644-1 cleanroom classifications.
- UNICORN® software-driven automation with full audit trail, electronic signatures, and role-based access control compliant with FDA 21 CFR Part 11 and EU Annex 11 requirements.
Sample Compatibility & Compliance
The OligoProcess™ supports synthesis of DNA, RNA, LNA, 2′-O-methyl, phosphorothioate (PS), and other modified oligonucleotides on standard controlled-pore glass (CPG) or polystyrene solid supports. Column formats include 10–100 mL synthesis vessels with customizable bed volumes and flow dynamics. All hardware and software components are validated per IQ/OQ/PQ protocols and designed to meet current Good Manufacturing Practice (cGMP) expectations for nucleic acid therapeutics. The system conforms to ISO 13485:2016 for medical device-related manufacturing processes and supports full documentation packages required for regulatory submissions to the FDA, EMA, PMDA, and Health Canada.
Software & Data Management
Controlled exclusively via Cytiva’s UNICORN® software platform (v7.4+), the OligoProcess™ provides end-to-end digital process management—from method creation and sequence import (FASTA, CSV) to real-time reaction monitoring, deviation detection, and electronic batch record (EBR) generation. All user actions, parameter changes, alarms, and instrument events are timestamped, digitally signed, and stored in a secure SQL Server database with immutable audit trails. Data export complies with ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available) and supports integration with MES, LIMS, and ERP systems via OPC UA and RESTful APIs.
Applications
- GMP-compliant production of antisense oligonucleotides (ASOs), siRNA, aptamers, and CRISPR guide RNAs for Phase I–III clinical trials and commercial supply.
- Scale-up of analytical reference standards and impurity panels used in QC release testing per USP and Ph. Eur. 5.2.12.
- Development of process robustness studies (DoE), lifecycle management, and comparability protocols following ICH Q5E and Q5F.
- Support for continuous manufacturing initiatives through synchronized reagent replenishment, predictive maintenance scheduling, and PAT-enabled endpoint detection.
FAQ
What synthesis scales does the OligoProcess™ support?
It delivers linear scalability from 10 µmol (early-stage lead optimization) to 1800 µmol (commercial batch sizes), with column configurations adaptable to 1–24 parallel syntheses.
Is the system qualified for GMP manufacturing?
Yes—the hardware, software, and documentation package are designed and validated for cGMP environments, supporting regulatory filings and routine inspection readiness.
Does it support modified nucleotides and non-standard backbones?
Yes—fully compatible with phosphorothioate linkages, 2′-modifications, base analogs, and dye-labeled phosphoramidites when used with appropriate reagent kits and column chemistries.
How is data integrity ensured during operation?
UNICORN® enforces 21 CFR Part 11 compliance via electronic signatures, audit trail encryption, automatic backup, and periodic integrity verification of all critical data sets.
Can the system integrate with existing manufacturing IT infrastructure?
Yes—it supports standardized communication protocols (OPC UA, MQTT, REST API) for seamless connectivity with MES, LIMS, and enterprise analytics platforms.
